The Integration of Chemotherapy and Surgery for Bladder Cancer

View More View Less
  • *‡ From the Genitourinary Oncology Service, Division of Solid Tumor Oncology, Department of Medicine, and Department of Urology, Memorial Hospital for Cancer and Allied Diseases, Memorial Sloan-Kettering Cancer Center, and the Joan and Stanford I. Weill Medical College of Cornel University, New York, New York.

Despite surgery with curative intent, approximately 50% of patients with muscle-invasive transitional cell carcinoma of the bladder will develop distant metastases and succumb to their disease. Attempts to improve outcomes have focused on refining surgical techniques and integrating perioperative chemotherapy. This review summarizes the available literature addressing the role of pelvic lymphadenectomy, neoadjuvant chemotherapy, and adjuvant chemotherapy in the management of patients with muscle-invasive transitional cell carcinoma of bladder.

If the inline PDF is not rendering correctly, you can download the PDF file here.

Correspondence: Matthew Galsky, MD, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021. E-mail: Galskym@mskcc.org
  • 1

    Stein JP, Lieskovsky G, Cote R. Radical cystectomy in the treatment of invasive bladder cancer: Long-term results in 1,054 patients. J Clin Oncol 2001;19:666675.

    • Search Google Scholar
    • Export Citation
  • 2

    Vieweg J, Gschwend JE, Herr HW. Pelvic lymph node dissection can be curative in patients with node positive bladder cancer. J Urol 1999;161:449454.

    • Search Google Scholar
    • Export Citation
  • 3

    Viewig J, Whitmore WF, Herr H. The role of pelvic lympadenectomy and radical cystectomy for lymph node positive bladder cancer: The Memorial Sloan-Kettering Cancer Center experience. Cancer 1994;73:30203028.

    • Search Google Scholar
    • Export Citation
  • 4

    Herr HW: Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality). BJU Int 2003;92:187188.

  • 5

    Herr HW: Extent of surgery and pathology evaluation has an impact on bladder cancer outcomes after radical cystectomy. Urology 2003;61:105108.

    • Search Google Scholar
    • Export Citation
  • 6

    Konety BR, Joslyn SA, O'Donnell MA. Extent of pelvic lymphadenectomy and its impact on outcome in patients diagnosed with bladder cancer: Analysis of data from the Surveillance, Epidemiology and End Results Program data base. J Urol 2003;169:946950.

    • Search Google Scholar
    • Export Citation
  • 7

    Herr HW, Faulkner JR, Grossman HB. Surgical factors influence bladder cancer outcomes: A cooperative group report. J Clin Oncol 2004;22:27812789.

    • Search Google Scholar
    • Export Citation
  • 8

    Herr H, Lee C, Chang S. Standardization of radical cystectomy and pelvic lymph node dissection for bladder cancer: A collaborative group report. J Urol 2004;171:18238; discussion 1827–828.

    • Search Google Scholar
    • Export Citation
  • 9

    Bajorin DF: Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer. J Clin Oncol 2001;19:17S20S.

    • Search Google Scholar
    • Export Citation
  • 10

    Splinter TA, Scher HI, Denis L. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer—Genitourinary Group. J Urol 1992;147:606608.

    • Search Google Scholar
    • Export Citation
  • 11

    Scher HI, Yagoda A, Herr HW. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol 1988;139:470474.

    • Search Google Scholar
    • Export Citation
  • 12

    Bassi P, Pagano F, Pappagallo G. Neo-adjuvant M-VAC of invasive bladder cancer: G.U.O.N.E. multicenter phase III trial (Abstr #567). Eur Urol 1998;33:142.

    • Search Google Scholar
    • Export Citation
  • 13

    Wallace DM, Raghavan D, Kelly KA. Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 1991;67:608615.

    • Search Google Scholar
    • Export Citation
  • 14

    Martinez-Pineiro JA, Gonzalez Martin M, Arocena F. Neoadjuvant cisplatin chemotherapy before radical cystectomy in invasive transitional cell carcinoma of the bladder: A prospective randomized phase III study. J Urol 1995;153:964973.

    • Search Google Scholar
    • Export Citation
  • 15

    Shipley WU, Winter KA, Kaufman DS. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: Initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol 1998;16:35763583.

    • Search Google Scholar
    • Export Citation
  • 16

    Cortesi E. Neoadjuvant treatment for locally advanced bladder cancer: A prospective randomized clinical trial (Abstr #623). Proc Am Soc Clin Oncol 1995;14:237.

    • Search Google Scholar
    • Export Citation
  • 17

    Hall R. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer (Abstr #710). Proc Am Soc Clin Oncol 2002;21:178a.

    • Search Google Scholar
    • Export Citation
  • 18

    Grossman HB, Natale RB, Tangen CM. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003;349:859866.

    • Search Google Scholar
    • Export Citation
  • 19

    Malmstrom PU, Rintala E, Wahlqvist R. Five-year followup of a prospective trial of radical cystectomy and neoadjuvant chemotherapy: Nordic Cystectomy Trial I. The Nordic Cooperative Bladder Cancer Study Group. J Urol 1996;155:19031906.

    • Search Google Scholar
    • Export Citation
  • 20

    Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 2003;361:19271934.

    • Search Google Scholar
    • Export Citation
  • 21

    Bono AV, Benvenuti C, Reali L. Adjuvant chemotherapy in advanced bladder cancer. Italian Uro-Oncologic Cooperative Group. Prog Clin Biol Res 1989;303:533540.

    • Search Google Scholar
    • Export Citation
  • 22

    Stockle M, Meyenburg W, Wellek S. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 1992;148:302306; discussion 306–307.

    • Search Google Scholar
    • Export Citation
  • 23

    Skinner DG, Daniels JR, Russell CA. The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer: a prospective comparative trial. J Urol 1991;145:459464; discussion 464–467.

    • Search Google Scholar
    • Export Citation
  • 24

    Studer UE, Bacchi M, Biedermann C. Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: results of a prospective randomized trial. J Urol 1994;152:8184.

    • Search Google Scholar
    • Export Citation
  • 25

    Freiha F, Reese J, Torti FM. A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle invasive bladder cancer. J Urol 1996;155:495499; discussion 499–500.

    • Search Google Scholar
    • Export Citation
  • 26

    Millikan R, Dinney C, Swanson D. Integrated therapy for locally advanced bladder cancer: Final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol 2001;19:40054013.

    • Search Google Scholar
    • Export Citation
  • 27

    von der Maase H, Hansen SW, Roberts JT. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 200;18:30683077.

    • Search Google Scholar
    • Export Citation
  • 28

    Dodd PM, McCaffrey JA, Herr H. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. J Clin Oncol 1999;17:25462552.

    • Search Google Scholar
    • Export Citation
  • 29

    Donat SM, Herr HW, Bajorin DF. Methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and cystectomy for unresectable bladder cancer. J Urol 1996;156:368371.

    • Search Google Scholar
    • Export Citation
  • 30

    Miller R, Freiha F, Reese J. Surgical restaging of patients with advanced transitional cell carcinoma of the urothelium treated with cisplatin, methotrexate, and vinblastine: Update of the Stanford University experience (Abstr). Proc Am Soc Clin Oncol 1992;10:167.

    • Search Google Scholar
    • Export Citation
  • 31

    Herr HW, Donat SM, Bajorin DF: Post-chemotherapy surgery in patients with unresectable or regionally metastatic bladder cancer. J Urol 2001;165:811814.

    • Search Google Scholar
    • Export Citation
  • 32

    Malmstrom PU, Rintala E, Wahlqvist R. Neoadjuvant cisplatin-methotrexate chemotherapy of invasive bladder cancer: Nordic cystectomy trial 2: XIVth Congress of the European Association of Urology (Abstr #238). Eur Urol 1999;35(Suppl 2):60.

    • Search Google Scholar
    • Export Citation
  • 33

    Abol-Enein H, El-Mekresh M, El-Baz M. Neoadjuvant chemotherapy in treatment of invasive transitional bladder cancer: A controlled prospective randomized study (Abstr #191). Br J Urol 1997;80(Suppl 2):49.

    • Search Google Scholar
    • Export Citation
All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 60 43 0
PDF Downloads 10 9 0
EPUB Downloads 0 0 0